Resumo

HERMIDA GUTIERREZ, Nelson H.; SANABRIA BECERRA, Lina M.  e  DIAZ ROJAS, Jorge A.. The assessment of pharmacoeconomic studies quality of Levodopa's use for the management of Parkinson's diseases, 2010-2015. Rev. colomb. cienc. quim. farm. [online]. 2017, vol.46, n.2, pp.256-277. ISSN 0034-7418.  https://doi.org/10.15446/rcciquifa.v46n2.67959.

Levodopa (LD) has been the first choice in the management of Parkinson's disease (PD), since its introduction in the drug market; however, its prolonged use is related to the occurrence of motor complications, affecting the functionality and quality of life. Parkinson's disease is one of the most frequent among the neurodegenerative diseases in the world, and it is expected that the number of people who suffer it, will increase due to global population aging. The PD represents, nowadays and for the future, a high economic burden from all perspectives, including patients, payers, and society. So it is necessary to know about the use of LD in its treatment and to realize the quality of pharmacoeconomic studies in the past five years, to identify reliable sources of information related to the costs and benefits of this medication to contribute in making decisions. The aim of this paper is to assess the methodological quality of pharmacoeconomic studies related to the use of LD in PD, specifically those that are identified as cost-utility studies, applying the QHES instrument. A total of19 articles were found, of which 5 met the inclusion criteria and were subjected to examination. The average overall score obtained after the evaluation was 77.2 out of 100, making evident a good quality of studies according to the method used.

Palavras-chave : Levodopa; Parkinson's disease; cost-utility; methodological quality; QHES (Quality of Health Economic Studies).

        · resumo em Espanhol     · texto em Inglês     · Inglês ( pdf )